RTP Mobile Logo
Visiting Professors: Investigator Perspectives on Recently Approved and Emerging Strategies in the Management of Breast Cancer
Released March 2020

Featuring perspectives from Dr Sara Hurvitz. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists and other healthcare providers involved in the treatment of breast cancer.

    LEARNING OBJECTIVES

    • Appraise recently presented Phase III data supporting the FDA approval of an antibody-drug conjugate as adjuvant therapy for patients with HER2-overexpressing early breast cancer who have residual invasive disease after neoadjuvant therapy with trastuzumab and taxane-based chemotherapy, and use this information to appropriately integrate this approach into routine practice.
    • Review published efficacy and safety data with the use of approved PARP inhibitors for patients with metastatic breast cancer harboring a BRCA1/2 mutation, and consider the diagnostic and therapeutic implications of these findings for nonresearch care.
    • Recall the biologic rationale for and design of ongoing clinical trials evaluating other investigational PARP inhibitors or novel PARP inhibitor combinations (eg, with immunotherapy or chemotherapy) for breast cancer, and counsel appropriate patients about availability and participation.
    • Appraise recently presented Phase III data supporting the FDA approval of anti-PD-L1 antibody therapy combined with chemotherapy for newly diagnosed PD-L1-positive metastatic triple-negative breast cancer, and use this information to identify patients who may be appropriate for this approach in clinical practice.
    • Recall the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies for breast cancer, and counsel appropriate patients about availability and participation.
    • Recognize the frequency of PI3K (phosphoinositide-3 kinase) pathway mutations in patients with ER-positive metastatic breast cancer, and consider published research data documenting the efficacy and safety of newly approved and novel agents targeting these abnormalities.
    • Assess ongoing clinical research evaluating novel agents and treatment strategies for metastatic HER2-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC) 
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/GrandRoundsBreast20/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: 

    Presenting Faculty Member

    Sara Hurvitz, MD
    Associate Professor of Medicine
    David Geffen School of Medicine at UCLA
    Director, Breast Cancer Clinical Research Program
    Co-Director, Santa Monica-UCLA Outpatient Oncology Practice
    Santa Monica, California

    Grant/Support: Ambryx Biotechnology, Amgen Inc, Bayer HealthCare Pharmaceuticals, BioMarin, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Dignitana, Genentech, a member of the Roche Group, GlaxoSmithKline, Lilly, MacroGenics Inc, Medivation Inc, a Pfizer Company, Merrimack Pharmaceuticals Inc, Novartis, OBI Pharma Inc, Pfizer Inc, Pieris Pharmaceuticals, Puma Biotechnology Inc, Roche Laboratories Inc, Seattle Genetics; Paid Travel: Lilly, Novartis, OBI Pharma Inc.

    Project Steering Committee Members

    Harold J Burstein, MD, PhD
    Professor of Medicine
    Harvard Medical School
    Breast Oncology Center
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    No financial interests or affiliations to disclose.

    Charles E Geyer Jr, MD
    Deputy Director
    Houston Methodist Cancer Center
    Houston, Texas

    Advisory Committee: Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Roche Laboratories Inc; Contracted Research: Genentech, a member of the Roche Group, Merck.

    Erika Hamilton, MD
    Director, Breast and Gynecologic Research Program
    Sarah Cannon Research Institute
    Nashville, Tennessee

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Lilly, Mersana Therapeutics, Novartis, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Silverback Therapeutics; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Aravive Inc, ArQule Inc, Arvinas, AstraZeneca Pharmaceuticals LP, BerGenBio ASA, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Deciphera Pharmaceuticals, eFFECTOR Therapeutics Inc, Eisai Inc, EMD Serono Inc, Fochon Pharmaceuticals Ltd, Fosun Orinove PharmaTech Inc, FUJIFILM Pharmaceuticals USA Inc, Genentech, a member of the Roche Group, H3 Biomedicine, Harpoon Therapeutics, Hutchison MediPharma, Immunomedics Inc, InventisBio, Leap Therapeutics Inc, Lilly, Lycera, MacroGenics Inc, Marker Therapeutics Inc, Medivation Inc, a Pfizer Company, Mersana Therapeutics, Merus BV, Molecular Templates, Novartis, NuCana, OncoMed Pharmaceuticals Inc, Pfizer Inc, Radius Health Inc, Regeneron Pharmaceuticals Inc, Rgenix, Roche Laboratories Inc, Seattle Genetics, Sermonix Pharmaceuticals, Silverback Therapeutics, Stemcentrx, Sutro Biopharma, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Torque Therapeutics, Unum Therapeutics, Verastem Inc, Zenith Epigenetics Ltd, Zymeworks.

    Rita Nanda, MD
    Director, Breast Oncology
    Associate Professor of Medicine
    Section of Hematology/Oncology
    The University of Chicago
    Chicago, Illinois

    Advisory Committee: Aduro Biotech, AstraZeneca Pharmaceuticals LP, Athenex, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, MacroGenics Inc, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Syndax Pharmaceuticals Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Corcept Therapeutics, Genentech, a member of the Roche Group, Immunomedics Inc, Merck, OBI Pharma Inc, Odonate Therapeutics, Pfizer Inc, Roche Laboratories Inc, Seattle Genetics; Data and Safety Monitoring Board/Committee: G1 Therapeutics.

    Joyce O’Shaughnessy, MD
    Celebrating Women Chair in Breast Cancer Research
    Baylor University Medical Center
    Director, Breast Cancer Research Program
    Texas Oncology
    US Oncology
    Dallas, Texas

    Advisory Committee and Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genomic Health Inc, GRAIL, Halozyme Inc, Heron Therapeutics, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Jounce Therapeutics, Lilly, Merck, Myriad Genetic Laboratories Inc, Novartis, Odonate Therapeutics, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Seattle Genetics, Syndax Pharmaceuticals Inc.

    Hope S Rugo, MD
    Professor of Medicine
    Director, Breast Oncology and Clinical Trials Education
    University of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Contracted Research: Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Odonate Therapeutics, Pfizer Inc, Seattle Genetics; Paid Travel: Amgen Inc, AstraZeneca Pharmaceuticals LP, Lilly, MacroGenics Inc, Merck, Mylan, Pfizer Inc, Puma Biotechnology Inc.

    Sara M Tolaney, MD, MPH
    Associate Director, Susan F Smith Center for Women’s Cancers
    Director of Clinical Trials, Breast Oncology
    Director of Breast Immunotherapy Clinical Research
    Senior Physician
    Breast Oncology Program
    Dana-Farber Cancer Institute
    Assistant Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Celldex Therapeutics, Eisai Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Sanofi Genzyme; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Eisai Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Pfizer Inc, Tesaro, A GSK Company; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Pfizer Inc, Roche Laboratories Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Merck, Novartis and Seattle Genetics.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: March 2020
    Expiration date: March 2021

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):